Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (9): 42-46.doi: 10.6040/j.issn.1671-7554.0.2022.0880

Previous Articles     Next Articles

Fertility protection and preservation in breast cancer patients

LIN Yun, XIE Yanqiu   

  1. Department of Reproductive Medicine, Guangdong Provincial Peoples Hospital;
    Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China
  • Published:2022-09-02

RichHTML

6

PDF (PC)

62

Abstract: Breast cancer is the most common female malignant tumor all over the world. With the promotion of breast cancer screening and the development of comprehensive treatment, the disease-free survival rate and overall survival rate of breast cancer patients have been greatly improved. Physicians are concerned about the infertility problem of young breast cancer patient, and fertility preservation is the most effective treatment. This article illustrates the effects of breast cancer treatment on ovarian function, strategies of fertility preservation and research progress in assisted reproduction for breast cancer patients, which provides evidence for fertility preservation among breast cancer patients in clinical practice.

Key words: Breast cancer, Fertility preservation, Ovarian function, Oocyte and embryo cryopreservation, Ovarian tissue cryopreservation

CLC Number: 

  • R737.9
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. LIU Zongchao, LI Zhexuan, ZHANG Yang, et al. Interpretation on the report of Global Cancer Statistics[J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 2021, 7(2): 1-13.
[3] Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year(1999-2008)retrospective clinical epidemiological study of female breast cancer in China[J]. BMC Cancer, 2011, 11: 364. doi: 10.1186/1471-2407-11-364.
[4] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update[J]. J Clin Oncol, 2018, 36(19): 1994-2001.
[5] Liem GS, Mo FK, Pang E, et al. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles[J]. PLoS One, 2015, 10(10): e0140842.
[6] Meirow D, Biederman H, Anderson RA, et al. Toxicity of chemotherapy and radiation on female reproduction[J]. Clin Obstet Gynecol, 2010, 53(4): 727-739.
[7] Overbeek A, van den Berg MH, van Leeuwen FE, et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review[J]. Cancer Treat Rev, 2017, 53: 10-24. doi: 10.1016/j.ctrv.2016.11.006.
[8] Minisini AM, Menis J, Valent F, et al. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era[J]. Anticancer Drugs, 2009, 20(6): 503-507.
[9] Tiong V, Rozita AM, Taib NA, et al. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer[J]. World J Surg, 2014, 38(9): 2288-2296.
[10] Shin JJ, Choi YM, Jun JK, et al. Amenorrhea and menopause in patients with breast cancer after chemotherapy[J]. J Breast Cancer, 2019, 22(4): 624-634.
[11] Furlanetto J, Marmé F, Seiler S, et al. Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials[J]. Eur J Cancer, 2021, 152: 193-203. doi: 10.1016/j.ejca.2021.04.038.
[12] Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies[J]. Eur J Cancer, 2017, 71: 34-42. doi: 10.1016/j.ejca.2016.10.030.
[13] Ganz PA, Cecchini RS, Fehrenbacher L, et al. NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab[J]. NPJ Breast Cancer, 2021, 7(1): 55-61.
[14] Cosgrove CM, Salani R. Ovarian effects of radiation and cytotoxic chemotherapy damage[J]. Best Pract Res Clin Obstet Gynaecol, 2019, 55: 37-48. doi: 10.1016/j.bpobgyn.2018.07.008.
[15] Wallace WHB, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries[J]. Int J Radiat Oncol Biol Phys, 2005, 62(3): 738-744.
[16] Mazonakis M, Varveris H, Damilakis J, et al. Radiation dose to conceptus resulting from tangential breast irradiation[J]. Int J Radiat Oncol Biol Phys, 2003 55(2): 386-391.
[17] 中国年轻乳腺癌诊疗与生育管理专家共识专家委员会. 年轻乳腺癌诊疗与生育管理专家共识[J]. 中华肿瘤杂志, 2019, 41(7): 486-495.
[18] Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer[J]. Cancer, 2010, 116(4): 791-798.
[19] Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab(APT trial)[J]. Breast Cancer Res Treat, 2015, 151(3): 589-596.
[20] Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 99-105.
[21] Huser M, Smardova L, Janku P, et al. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues[J]. J Assist Reprod Genet, 2015, 32(8): 1187-1193.
[22] Horicks F, Van Den Steen G, Houben S, et al. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model[J]. PLoS One, 2015, 10(9): e0137164.
[23] Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and Meta-analysis[J]. JAMA Oncol, 2016, 2(1): 65-73.
[24] Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and Meta-analysis of individual patient-level data[J]. J Clin Oncol, 2018, 36(19):1981-1990.
[25] Moore HCF, Unger JM, Phillips KA, et al. Final analysis of the prevention of early menopause study(POEMS)/SWOG Intergroup S0230[J]. J Natl Cancer Inst, 2019, 111(2): 210-213.
[26] Zong X, Yu Y, Yang H, et al. Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial[J]. JAMA Oncol, 2022, 8(2): 252-258.
[27] Preservation TEGGoFF. ESHRE FFP Guideline: female fertility preservation[J]. Hum Reprod Open, 2020: 1-17.
[28] 中华医学会生殖医学分会. 生育力保存中国专家共识[J]. 生殖医学杂志, 2021, 30(9): 1129-1134. Chinese Society of Reproductive Medicine. Chinese expert consensus on fertility preservation[J]. Journal of Reproductive Medicine, 2021, 30(9): 1129-1134.
[29] 中国妇幼保健协会生育力保存专业委员会. 女性生育力保存临床实践中国专家共识[J]. 中华生殖与避孕杂志, 2021, 41(5): 383-391.
[30] Dolmans MM, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue[J]. Fertil Steril, 2013, 99(6): 1514-1522.
[31] Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review[J]. Hum Reprod, 2017, 32(5): 1033-1045.
[32] Letourneau JM, Wald K, Sinha N, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation[J]. Cancer, 2020, 126(3): 487-495.
[33] Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy[J]. J Clin Endocrinol Metab, 2006, 91(10): 3885-3890.
[34] Turan V, Bedoschi G, Emirdar V, et al. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes[J]. Reprod Sci, 2018, 25(1): 26-32.
[35] Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study[J]. Hum Reprod, 2020, 35(4): 929-938.
[36] Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation[J]. J Clin Oncol, 2005, 23(19): 4347-4353.
[37] Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation[J]. Reprod Biomed Online, 2010, 20(6): 783-788.
[38] Goldrat O, Van Den Steen G, Gonzalez-Merino E, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers[J]. Reprod Biol Endocrinol, 2019, 17(1): 3-11.
[39] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416.
[40] Turan V, Demeestere I, Lambertini M, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a Meta-analysis of individual patient-level data[J]. J Clin Oncol, 2021, 39(18): 2016-2024.
[41] Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer[J]. Oncologist, 2012, 17(11): 1409-1417.
[42] Derks-Smeets IA, de Die-Smulders CE, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors[J]. Breast Cancer Res Treat, 2014, 145(3): 673-681.
[43] Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: does timing of conception affect infant health?[J]. Cancer, 2018, 124(22): 4401-4407.
[44] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040.
[1] Guimin HAO,Zhuoye LUO,Yizhuo WANG. Ethical issues and considerations in fertility preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 47-52.
[2] WU Ruifang, LI Changzhong. Status and progress of female fertility protection [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 1-7.
[3] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[4] SHI Yuhua, PAN Ye, XIE Yanqiu. Latest advances of embryo cryopreservation technology [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 12-18.
[5] LU Qun, ZHAO Lulu. Progress on assisted reproductive technology for women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertilitysparing treatment [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 35-41.
[6] YAN Lei, YUE Caixin, LIU Yichun. Fertility preservation in patients with endometriosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 31-34.
[7] YANG Qifeng, ZHANG Ning. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[8] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[9] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[10] FENG Haigang, LIU Guowen, CAO Hong. Effects and mechanism of interfering MAD2L1 gene expression on the apoptosis of breast cancer cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 9-16.
[11] CHU Zhuxiu, ZHAO Wenjing, LI Xiaoyan, KONG Xiaoli, MA Tingting, JIANG Liyu, YANG Qifeng. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[12] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[13] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[14] ZHU Xuli, ZHOU Liang, WANG Yue, SUN Qingyun, CAO Mingya, DU Yuanjie, CAO Jinfeng, ZHAO Zhiming, HAO Guimin. Correlation analysis of freezing methods with different sperm sources and pregnancy outcomes [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 86-93.
[15] KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[2] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[3] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[4] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[5] XU Yuxiang, LIU Yudong, ZHANG Peng, DUAN Ruisheng. A retrospective analysis of risk factors of cerebral microbleeds in 101 patients with cerebral small vessel disease[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 67 -71 .
[6] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[7] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[8] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[9] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
[10] LI Songlin, LIU Peilai, LU Qunshan, MA Heran. Application of high tibial osteotomy combined with autologous adipose-derived mesenchymal stem cells injection in the repair of knee cartilage[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 82 -88 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd